Acrivon Therapeutics, Inc.
News
Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference
Globe Newswire WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ( Acrivon or Acrivon Therapeutics ) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its...\n more…
Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316
Globe Newswire -Webcast investor event on September 14, 2024 at 9:00 a.m. ET -ESMO poster presentation to provide updated ACR-368 clinical data in endometrial cancer -Webcast to provide updates on its lead...\n more…
Acrivon Therapeutics (NASDAQ:ACRV) Given "Buy" Rating at Piper Sandler Companies
Ticker Report Piper Sandler Companies reiterated their buy rating on shares of Acrivon Therapeutics (NASDAQ:ACRV - Free Report) in a research report sent to investors on Friday, Stock Target Advisor reports. The...\n more…
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts
Zolmax Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six research firms that are presently covering the firm...\n more…
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Recommendation of "Moderate Buy" by Analysts
Ticker Report Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has received an average recommendation of "Moderate Buy" from the six research firms that are covering the company, Marketbeat.com reports...\n more…